Prosecution Insights
Last updated: November 20, 2026
Application No. 18/015,108

NUTRITIONAL COMPOSITION COMPRISING MIR-3184

Final Rejection §101§112
Filed
Jan 09, 2023
Priority
Jul 10, 2020 — EU 20185309.0 +1 more
Examiner
ZARA, JANE J
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nestlé S.A.
OA Round
4 (Final)
71%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
788 granted / 1109 resolved
+11.1% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
49 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
5.4%
-34.6% vs TC avg
§103
30.6%
-9.4% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1109 resolved cases

Office Action

§101 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office action is in response to the communications filed 4-9-26 and 5-12-26. Claims 17, 19-36 are pending in the instant application. Response to Arguments and Amendments Withdrawn Objections/Rejections Any objections or rejections not repeated in this Office action are hereby withdrawn. Maintained Rejections Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 17, 19-36 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claims are drawn to compositions, methods of consumption, and methods of testing the consumption of miR-3184 and optionally further comprising let-7b, let-7c, miR-19b, miR-22, miR-24, miR-25, miR-29a, miR-30a, miR-92a, miR-99a, miR-100, miR-197, miR-30d, miR-181a, miR-181b, miR-205, miR-210, miR-221, miR-125b, miR-125a, miR-149, miR-193a, miR-320a, miR-200a, miR-99b, miR-130b, miR-30e, miR-375, miR-378a, miR-151a, miR-425, miR-484, miR-146b, miR-574, miR-652, miR-320c, miR-3141, let-7d, miR-196a, miR-187, miR-516a, miR-92b, and miR-3126, let-7d, miR-196a, miR-187, miR-516a, miR-92b, miR-3126, miR-3141 and/or miR-3126. Claims 17, 19-25, 27-35 are rejected because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claimed invention is directed to products of nature without significantly more. The claim(s) recite(s) products of nature including various microRNA molecules (a.k.a. mir molecules). This judicial exception is not integrated into a practical application because they recite products of nature. The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because they recite compositions comprising products of nature. He claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claimed invention is directed to non-statutory subject matter. The claimed invention is directed to products of nature comprising compositions of mir molecules. These molecules are naturally occurring. What’s more, the claims do not include any elements that add significantly more to any judicial exceptions, and do not include features that demonstrate that the recited products are markedly different from what exists in nature. The molecules perform in their natural way, serve the ends nature originally provided, and act quite independently of any effort of patentee. There are no marked differences in the function or structure of these naturally occurring molecules, and their characteristics do not change from that occurring in nature. In sum when the relevant factors are analyzed, they weigh toward ineligibility under 35 U.S.C. 101. Therefore, the claims are non-statutory, and the rejection under 35 U.S.C. 101 is appropriate. Applicant’s Arguments Applicant's arguments filed 9-3-26 have been fully considered but they are not persuasive. Applicant argues the following: Applicant respectfully disagrees. For example, the assertion by the Patent Office "there are no covalent or other modifications to the miR molecules"⁵ does not account for other examples that are more analogous to Claim 17 and demonstrate this claim is directed to patent eligible subject matter. In this regard, the "2014 Interim Guidance on Patent Subject Matter Eligibility" issued on December 16, 2014, (hereafter "2014 Guidelines") establishes that the analysis for markedly different characteristics of a nature-based product that combines multiple components should be applied to the resultant nature-based combination, rather than its component parts. Furthermore, markedly different characteristics include structure, function and/or other properties, and even a small change can result in markedly different characteristics from the naturally occurring counterpart… Along with the 2014 Guidelines, the Patent Office provided a "Nature-Based Products" document in support of the same. This supporting document contains "examples [that] should be used in conjunction with the 2014 Interim Eligibility Guidance. Regarding independent Claim 17, the 2014 Guidelines provide several examples of patent eligible composition claims. For example, Claim 2 of Example 2 includes a beverage composition comprising pomelo juice and an effective amount of an added preservative. The analysis provided by the Patent Office notes that "there is no naturally occurring counterpart to the claimed combination, so the combination is compared to the individual components as they occur in nature." Then, in comparing the claimed combination with the naturally occurring juice, the Patent Office concludes that the claim is directed to patent eligible subject matter because the slower spoiling property of the claimed combination is "markedly different from properties of the juice by itself in nature. Accordingly, the claimed combination has markedly different characteristics, and is not a 'product of nature' exception. Analogously, independent Claim 17 recites, in part, a composition comprising miR-3184, wherein the nutritional composition is in a form selected from the group consisting of an infant formula, an infant formula fortifier and a breast milk fortifier, and wherein the nutritional composition is not natural human or animal milk. The Patent Office does not allege that there is a naturally occurring counterpart to the claimed combination, so the presently claimed combination should be compared to the individual components as they occur in nature. While miR-3184 may occur in nature, the skilled artisan understands that the recitation of "wherein the nutritional composition is in a form selected from the group consisting of an infant formula, an infant formula fortifier and a breast milk fortifier, and wherein the nutritional composition is not natural human or animal milk" is not naturally occurring. For example, it is well understood in the art that "breast milk fortifiers" and "infant milk fortifiers" are specialized nutritional supplements and do not refer to products of nature. In particular, "to fortify" is understood, in the context of nutrition, as "to enrich (food) by adding ingredients (such as vitamins or minerals) to improve the nutritional value." Additionally, an "infant formula" is well understood to refer to a nutritional composition intended for infants during the first year of life. Such compositions are understood to satisfy the nutritional requirements for the infant by including necessary proteins, lipids, carbohydrates and other nutrients. Claim 17 further recites that the nutritional composition is not natural human or animal milk. Accordingly, an infant formula is not a naturally occurring product. Moreover, the specification defines "nutritional composition" as "a composition which nourishes a subject" and "does not include natural milk of human or animal origin." Thus, these terms also exclude natural milk. Accordingly, the recited nutritional composition in a form selected from the group consisting of an infant formula, a breast milk fortifier, and an infant formula fortifier is not a product of nature. Therefore, even if Claim 17 recites a product of nature, the claimed composition, as a whole, is a composition with markedly different characteristics than that alleged to naturally occur.. Response to Applicant’s Arguments Contrary to Applicant’s assertions, the claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception. The nucleic acids or miR molecules claimed have no difference from naturally occurring products. The claims, including compositions containing infant formula and fortifiers, and methods of feeding them, do not include any elements that add significantly more to any judicial exceptions, and do not include features that demonstrate that the recited products are markedly different from what exists in nature. Applicant is correct that the "2014 Interim Guidance on Patent Subject Matter Eligibility" issued on December 16, 2014, (hereafter "2014 Guidelines") sets forth an analysis for markedly different characteristics of a nature-based product. But, contrary to Applicant’s arguments and assertions, the instantly claimed subject matter is directed to compositions and methods in combination with naturally occurring nucleic acid molecules, whether isolated or not, that are not patent eligible pursuant to the Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. (6-13-13). The closest naturally occurring counterpart is natural, human breast milk. Example 1 did iRNA profiling of natural human breast milk (e.g., specification at page 29). Table 1 shows expression of hsa-miR-3184-3p during lactation (e.g., specification at page 31). Thus, the specification provides evidence that the closest naturally occurring counterpart is human breast milk. The question is whether the claimed composition is markedly different than natural, human breast milk. See MPEP 2106.04(c)(I)(A), which states the following: Where the claim is to a nature-based product produced by combining multiple components (e.g., a claim to "a probiotic composition comprising a mixture of Lactobacillus and milk"), the markedly different characteristics analysis should be applied to the resultant nature-based combination, rather than its component parts. For instance, for the probiotic composition example, the mixture of Lactobacillus and milk should be analyzed for markedly different characteristics, rather than the Lactobacillus separately and the milk separately. Identifying Appropriate Characteristics for Analysis: See MPEP 2106.04(c)(II)(B). Evaluating Characteristics to Determine Whether They Are Markedly Different: In order to be markedly different, the inventor must have caused the claimed product to possess at least one characteristic that is different from that of the counterpart Attempting to make the infant formula more like the natural counterpart, breast milk, would not make the natural miR molecules markedly different. Therefore, the claims of miR molecules amount to nothing more than obvious derivatives of natural occurring products and steps intending to utilize them. For these reasons, the instant rejection is properly maintained. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 24-27, 30-35 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an in vitro Caco2 cell model for evaluating the effect of miR-3184-3p, miR-3126-5p, and miR-3141 on gene expression, does not reasonably enable methods of feeding or evaluating the effects on human infants of consuming a nutritional composition comprising miR-3184, or methods to modulate gene expression of one or more genes selected from Lipin 2 and Insulin Like Growth Factor 2 using miR-3184 in vivo. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims for the reasons of record set forth in the Office action mailed 6-29-26, and for the reasons set forth below. Applicant’s Arguments Applicant's arguments filed 9-3-26 have been fully considered but they are not persuasive. Applicant argues the following: Applicant traverses the enablement rejection of independent Claim 26 for at least the reasons that follow. First, the skilled artisan, weighing the evidence as a whole, understands that the preponderance of the evidence before the Patent Office overwhelmingly weighs in favor of concluding Claim 26 is enabled.13 MPEP explains "[a] declaration or affidavit is, itself, evidence that must be considered."14 After such a declaration is filed,[t]he examiner must then weigh all the evidence of record, including the specification, any new evidence supplied by applicant, and any evidence and scientific reasoning previously presented in the rejection and then decide whether the claimed invention is enabled, based on a preponderance of the evidence standard. The examiner should never make this determination based on personal opinion. The determination should always be based on the weight of all the evidence of record. In this regard, the Patent Office did not weigh the evidence provided in the Declaration under 37 CFR 1.132 ("Declaration") or Exhibits A-D ("Exhibits") enclosed with the Response in reply to the Final Office Action dated January 14, 2026. Instead, the Patent Office merely reproduced the Applicant's previous arguments without addressing their merits or weighing the evidence in the Declaration or Exhibits cited therein.16 This was improper. For example, the Declaration evidences: The other inventors and I surprisingly found that miR-3184 significantly increases the expression of both Lipin-2 and IGF2. These findings were made using an in vitro evaluation of Caco-2 cells, a human colon adenocarcinoma cell line widely used and understood to be the gold standard in vitro model for predicting human intestinal drug absorption and permeability. Cells transfected with miR- 3184 exhibited a 1.54 log fold change in expression of the Lipin-2 gene and a 1.72 log fold change in expression of IGF2 compared to control cells. Exhibits A and B further describe in vivo evidence demonstrating that orally administered milk-derived miRNAs can be detected beyond the intestinal lumen, including in peripheral blood mononuclear cells, plasma, and distant organs. Human and animal studies summarized in Exhibit A report dose-dependent increases in specific milk-derived miRNAs following milk consumption, indicating not only survival through digestion but also systemic bioavailability at biologically meaningful levels (Ex. A, § 5; Table 1). Importantly, the literature establishes that milk-derived EVs may enter systemic circulation while retaining their miRNA cargo and that such vesicles can cross additional biological barriers, including the blood-brain barrier. These observations, described in both Exhibit A and Exhibit B, further support the conclusion that milk-derived miRNAs remain structurally intact and functionally competent after oral administration (Ex. A, § 6; Ex. B, § 5). Accordingly, it is my opinion that a person of ordinary skill in the art would understand that milk-based miRNAs are not fragile dietary remnants, but rather purposefully protected bioactive molecules. Their demonstrated stability in gastrointestinal conditions and their documented uptake by mammalian cells reflect evolved biological mechanisms facilitating intercellular communication, particularly in the context of maternal-infant nutrition. For these reasons, I conclude that the scientific evidence supports the proposition that miRNAs, and especially milk-derived miRNAs, are stable during digestion and are capable of being absorbed in the human gastrointestinal tract, where they may exert local and systemic biological effects (Ex. A; Ex. B).21 Additionally, based on my review and expertise, it is my opinion that IGF2 is a central and evolutionarily conserved regulator of normal postnatal growth and tissue development. Exhibit C explains that IGF-II promotes cell growth, survival, migration, and differentiation, and that IGF-I and IGF-II are essential for normal fetal and postnatal growth (Ex. C, pp. 176-177). Disruption of IGF signaling leads to impaired growth, whereas physiologically appropriate IGF-II availability provides anabolic support to developing tissues following birth (Ex. C, p. 176). The scientific literature further demonstrates that appropriate IGF2 expression during early life supports long-term metabolic health. Exhibit C describes IGF-II as an endocrine and paracrine regulator influencing glucose metabolism and anabolic balance, acting primarily through the IGF-1 receptor with high affinity (Ex. C, pp. 176-177). Altered IGF-II availability is associated with abnormal metabolic responses, whereas regulated IGF-II action supports proportional growth without pathological adiposity (Ex. C, pp. 176-178). A person of ordinary skill in the art would therefore understand that promoting IGF2 expression within a physiological range during postnatal development reduces vulnerability to later-life metabolic disorders such as insulin resistance. Furthermore, in my opinion, Lipin-2 plays a complementary role in establishing postnatal metabolic resilience. Exhibit D identifies Lipin-2 as a magnesium-dependent phosphatidic acid phosphatase involved in triglyceride synthesis and lipid homeostasis and further explains that Lipin-2 expression levels directly regulate cellular lipid handling capacity (Ex. D, pp. 10894-10896). Proper Lipin-2 expression facilitates incorporation of fatty acids into neutral lipid stores, reducing lipotoxic stress at the cellular level (Ex. D, pp. 10897-10899). Exhibit D further demonstrates that Lipin-2 suppresses chronic inflammatory signaling linked to metabolic disease. Specifically, depletion of Lipin-2 results in overstimulation of the JNK1/c-Jun pathway and increased expression of pro-inflammatory cytokines including TNF-a, IL-6, and CCL2 (Ex. D, pp. 10896-10899, Figs. 2-6). Conversely, overexpression of Lipin-2 reduces inflammatory gene expression and limits macrophage-mediated inflammatory responses to saturated fatty acids (Ex. D, pp. 10897-10900). These inflammatory pathways are widely recognized contributors to obesity-associated insulin resistance. Chronic low-grade inflammation and impaired lipid partitioning during early life are known predictors of later metabolic dysfunction. Exhibit D explicitly identifies Lipin-2 as a protective regulator linking lipid metabolism and inflammation and demonstrates its relevance to obesity and type 2 diabetes pathophysiology (Ex. D, pp. 10894-10895, 10899-10902). A person of ordinary Applicant's "findings were made using an in vitro evaluation of Caco-2 cells, a human colon adenocarcinoma cell line. Declaration, paras. 13-19 (bold added). 25 Office Action, page 8-9 (annotation added). 26 See Specification, Example 2 - In Vitro Evaluation of miR-3184 predicting human intestinal drug absorption and permeability." Response to Applicant’s Arguments Applicant's arguments filed 9-3-26 have been fully considered but they are not persuasive. It is noted that Applicant has provided evidence using an in vitro evaluation of Caco-2 cells, a human colon adenocarcinoma cell line widely used and understood to be the gold standard in vitro model for predicting human intestinal drug absorption and permeability. It is noted that the in vitro test in Caci-2 cells showed an increase in expression of various genes upon transfection with miR molecules as described below. The Breadth of the Claims: The claims are drawn to methods of administering a nutritional composition comprising miR-3184 to a human infant optionally between 3-6 months of age, which nutritional composition optionally comprises an infant formula, an infant formula fortifier, or a breast milk fortifier, the claims are also drawn to a method for evaluating the effect of miR-3184-3p, miR-3126-5p, and miR-3141 on gene expression of one or more genes selected from Lipin 2 or Insulin Like Growth Factor 2 in vivo, which miR-3184 is present in a concentration of 100-1000 pmol/L, which nutritional composition is optionally administered orally, further comprising mixing, before the administering, the infant formula fortifier with infant formula or the breast milk fortifier with breast milk, wherein the nutritional composition is optionally a powder reconstituted into a liquid composition for feeding an infant comprising administering a nutritional composition comprising miR-3184, and methods to modulate gene expression of one or more genes selected from Lipin 2 and Insulin Like Growth Factor 2 using miR-3184 in a subject. The claims, however, encompass the in vivo testing in human infants comprising the administration of a dosing regimen of the various miR molecules listed in the claims. The Teachings in the Art: The biological roles or miR-3184 are complex and are still being investigated. The state of the art regarding miR-3184, its targets, and its role on growth and development in animals including humans has not been fully determined. See, e.g., Xu et al (Cancer Science, Vol. 113, No. 8, pages 2668-2680 (2021)), describing the enrichment of miR-3184 in cerebrospinal fluid exosomes in glioma patients. MiR-3184 was found to significantly promote glioma progression and invasion. Sauter et al (NC Med. J., Vol. 68, No. 2, pages 132-135 (2007)) review the regulations and requirements for laboratory testing on humans to ensure quality testing. Quality standards for testing require compliance of patient test management, personnel qualifications, quality assurance, and quality control (see entire document, esp. page 132). Psaty et al (Arch. Intern. Med., Vol. 160, pages 2577-2580 (2000)) discuss the national guidelines for clinical trials and the quality of evidence required for evaluating in vivo trials in humans. Confidence in the findings of randomized clinical trials is directly related to quality, importantly including adequate randomization, blinding and complete follow up for ascertainment of primary events (page 2577). The Teachings in the Specification: As stated previously, the specification teaches the following: Eleven dynamic miRNAs were identified with either an increasing or a decreasing expression during lactation. These are shown in Tables 1 and 2 ... Thirty-eight miRNAs were identified which were highly and stably expressed during lactation. These are shown in Table 3… Cell culture and transfection Caco2 were cultured in DMEM (+) L-glutamate (-) Pyruvate supplemented with 1X non-essential amino acids, 1mM Sodium Pyruvate and 20 % FBS. Cells were split three times a week without exciding 80% confluency. For transfection, cells were plated in 24 well plate (50,000 cells / well) to obtain a 50% confluency the day after. Transfection was performed using DharmaFect reagent from Dharmacon… following manufacturer recommendation. Briefly, 1.25 ul / well of DharmaFect 4 and a final concentration of 25 nM of miRNA were used. For each time point (i.e. 48h and 72h post transfection) media was removed and cells were washed with 1 ml of cold PBS without calcium chloride and magnesium chloride. Cells were frozen directly on plate after aspirating cold PBS. miRNA were purchased from Dharmacon…, see P 33. An in vitro Caco2 cell model was used to evaluate the effect of miR-3184-3p, miR-3126-5p, and miR-3141 on gene expression. miR-3184-3p, miR-3126-5p, and miR-3141 significantly affected the expression of the genes shown in Table 4… [Citations omitted] [Emphases added]. Contrary to Applicant’s assertions, the examples provided in the instant specification, of an in vitro Caco2 cell model for evaluating the effect of miR-3184-3p, miR-3126-5p, and miR-3141 on gene expression, comprising Caco2 cultured in DMEM (+) L-glutamate (-) Pyruvate supplemented with 1X non-essential amino acids, 1mM Sodium Pyruvate and 20 % FBS, are not representative or correlative of the ability to test infants for any effects including the modulation of Lipin 2 and Insulin Like Growth Factor 2 using miR-3184. There are no teachings in the specification as to the ability to test the advantages of consumption of the miR molecules over the concentration ranges claimed or for the provision of in vivo effects, including in infants, as instantly claimed. In light of the teachings in the art and the specification, one skilled in the art would not accept on its face the examples provided in the instant disclosure, and as summarized above, as being correlative or representative of the ability to test the consumption of the miR molecules and their effects as claimed in an infant. Since the specification fails to provide the requisite guidance for any in vivo protocols for testing in a subject, and since determination of the factors required for accomplishing these are highly unpredictable, it would require undue experimentation to practice the invention over the broad scope claimed. For the aforementioned reasons, the instant rejection under 35 U.S.C. 112, first paragraph is properly maintained. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Certain papers related to this application may be submitted to Art Unit 1637 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. The examiner’s office hours are generally Monday-Friday, 10:30am - 7pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jennifer Dunston, can be reached on (571)-272-2916. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Jane Zara 10-25-26 /JANE J ZARA/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Show 8 earlier events
Apr 08, 2026
Response after Non-Final Action
May 12, 2026
Request for Continued Examination
May 19, 2026
Response after Non-Final Action
Jun 29, 2026
Non-Final Rejection mailed — §101, §112
Jul 30, 2026
Applicant Interview (Telephonic)
Aug 03, 2026
Examiner Interview Summary
Sep 03, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799147
RIBONUCLEIC ACID PURIFICATION
3y 6m to grant Granted Nov 17, 2026
Patent 12774468
DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES
3y 1m to grant Granted Oct 27, 2026
Patent 12735704
ANTICANCER ADJUVANT AND PHARMACEUTICAL COMPOSITION FOR TREATING ANTICANCER-AGENT-RESISTANT CANCER, AND KIT COMPRISING SAME
3y 11m to grant Granted Sep 15, 2026
Patent 12734251
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
3y 7m to grant Granted Sep 15, 2026
Patent 12703734
METHOD OF ASSESSING ACTIVITY OF RECOMBINANT ANTIGEN RECEPTORS
2y 9m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
71%
Grant Probability
87%
With Interview (+16.1%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1109 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month